Eiger BioPharmaceuticals Statistics Share Statistics Eiger BioPharmaceuticals has 1.48M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 1.48M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 1.27M Failed to Deliver (FTD) Shares 982 FTD / Avg. Volume 0.74%
Short Selling Information The latest short interest is 29.81K, so 0% of the outstanding
shares have been sold short.
Short Interest 29.81K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.06
Valuation Ratios The PE ratio is -0.13 and the forward
PE ratio is -0.64.
Eiger BioPharmaceuticals's PEG ratio is
0.
PE Ratio -0.13 Forward PE -0.64 PS Ratio 0.63 Forward PS 0.1 PB Ratio -0.69 P/FCF Ratio -0.13 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Eiger BioPharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.71,
with a Debt / Equity ratio of -2.85.
Current Ratio 0.71 Quick Ratio 0.68 Debt / Equity -2.85 Debt / EBITDA -0.6 Debt / FCF -0.55 Interest Coverage -13.13
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $281.66K Profits Per Employee $-1.34M Employee Count 56 Asset Turnover 0.41 Inventory Turnover 0.02
Taxes Income Tax 6K Effective Tax Rate -0.01%
Stock Price Statistics The stock price has increased by -28.81% in the
last 52 weeks. The beta is 1.84, so Eiger BioPharmaceuticals's
price volatility has been higher than the market average.
Beta 1.84 52-Week Price Change -28.81% 50-Day Moving Average 3.75 200-Day Moving Average 9.4 Relative Strength Index (RSI) 36.83 Average Volume (20 Days) 131,879
Income Statement In the last 12 months, Eiger BioPharmaceuticals had revenue of 15.77M
and earned -74.96M
in profits. Earnings per share was -50.78.
Revenue 15.77M Gross Profit 15.75M Operating Income -71.79M Net Income -74.96M EBITDA -68.74M EBIT -69.49M Earnings Per Share (EPS) -50.78
Full Income Statement Balance Sheet The company has 25.44M in cash and 41.2M in
debt, giving a net cash position of -15.76M.
Cash & Cash Equivalents 25.44M Total Debt 41.2M Net Cash -15.76M Retained Earnings -512.16M Total Assets 38.83M Working Capital -15.45M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -74.55M
and capital expenditures -234K, giving a free cash flow of -74.78M.
Operating Cash Flow -74.55M Capital Expenditures -234K Free Cash Flow -74.78M FCF Per Share -50.66
Full Cash Flow Statement Margins Gross margin is 99.85%, with operating and profit margins of -455.12% and -475.26%.
Gross Margin 99.85% Operating Margin -455.12% Pretax Margin -475.22% Profit Margin -475.26% EBITDA Margin -435.81% EBIT Margin -455.12% FCF Margin -474.11%
Dividends & Yields EIGR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for EIGR.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 8, 2024. It was a
backward
split with a ratio of 1:30.
Last Split Date Jan 8, 2024 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -24.48 Piotroski F-Score 4